CytomX Therapeutics, Inc. (CTMX) stock forecast and price target
Price $2.04 · data as of November 13, 2026
12-month price target
Average target$12.38
Upside / downside+506.6%
Analysts8
ConsensusStrong buy
Low $5.00Average $12.38High $16.00
Gold marker: average target · white marker: today’s price ($2.04)
Analyst ratings
Strong buy 3Buy 5Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.39 | −158.2% | $22M |
| Next fiscal year ends December 31, 2027 | $-0.50 | −28.7% | $26M |
| Next quarter ends December 31, 2026 | $-0.08 | +62.7% | $10M |
| Quarter after ends March 31, 2027 | $-0.10 | −1.6% | $5M |
Consensus of the analysts covering CytomX Therapeutics, updated daily. In the last 30 days 0 estimates were raised and 1 lowered.
Frequently asked questions
What is the CytomX Therapeutics stock price target?
The average 12-month target from 8 analysts is $12.38, 506.6% above the current price of $2.04 Targets range from $5.00 to $16.00.
Is CytomX Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (3 strong buy, 5 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is CytomX Therapeutics expected to earn?
Analysts expect EPS of $-0.39 for the fiscal year ending December 31, 2026 and $-0.50 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.